8.70
Ginkgo Bioworks Holdings Inc stock is traded at $8.70, with a volume of 866.28K.
It is up +3.15% in the last 24 hours and up +10.23% over the past month.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
See More
Previous Close:
$8.41
Open:
$8.63
24h Volume:
866.28K
Relative Volume:
0.71
Market Cap:
$568.32M
Revenue:
$170.16M
Net Income/Loss:
$-312.76M
P/E Ratio:
-1.5307
EPS:
-5.6837
Net Cash Flow:
$-178.72M
1W Performance:
+17.87%
1M Performance:
+10.23%
6M Performance:
-4.77%
1Y Performance:
+24.11%
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Name
Ginkgo Bioworks Holdings Inc
Sector
Industry
Phone
(877) 442-5362
Address
27 DRYDOCK AVENUE, BOSTON
Compare DNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
DNA
Ginkgo Bioworks Holdings Inc
|
8.70 | 549.38M | 170.16M | -312.76M | -178.72M | -5.6837 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-24 | Downgrade | BTIG Research | Neutral → Sell |
| May-10-24 | Downgrade | William Blair | Mkt Perform → Underperform |
| Nov-14-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-09-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-02-23 | Downgrade | Goldman | Neutral → Sell |
| May-11-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-29-22 | Initiated | Berenberg | Buy |
| Oct-04-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-18-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Feb-23-22 | Initiated | Goldman | Neutral |
| Feb-01-22 | Initiated | BofA Securities | Neutral |
| Jan-28-22 | Initiated | BofA Securities | Buy |
| Jan-07-22 | Initiated | BTIG Research | Buy |
| Nov-29-21 | Initiated | Jefferies | Buy |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Oct-12-21 | Initiated | William Blair | Outperform |
| Sep-20-21 | Initiated | HSBC Securities | Buy |
View All
Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News
New AI lab service aims for fewer dead ends in drug discovery - Stock Titan
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts - MSN
Ginkgo Bioworks Holdings (DNA) Price Target Decreased by 11.11% to 10.88 - MSN
Steve Coen (DNA) files Form 144 to sell 307 Class A shares - Stock Titan
Ginkgo Bioworks Holdings Inc (DNA): What’s the Future of Autonomous Lab? - Yahoo Finance
DNA Technical Analysis | Trend, Signals & Chart Patterns | GINKGO BIOWORKS HOLDINGS INC (NYSE:DNA) - ChartMill
Trading the Move, Not the Narrative: (DNA) Edition - Stock Traders Daily
Ginkgo Bioworks Announces Presentations at the Upcoming American - GuruFocus
Viking Global (DNA) reports 3,577,128 shares, removes retired reporting person - Stock Titan
Ginkgo Bioworks (DNA) 10K Form and Latest SEC Filings 2026 - MarketBeat
Ginkgo Bioworks Holdings, Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:DNA) 2026-05-13 - Seeking Alpha
Ginkgo Bioworks slumps 14% after projecting FY26 cash burn of $125M-$150M - MSN
Ginkgo outlines $125M-$150M 2026 cash burn guidance while expanding Nebula to 103 racks - MSN
Ginkgo Bioworks: Another Lost Year (NYSE:DNA) - Seeking Alpha
Austin Che files Form 144 to sell Class A shares (NASDAQ: DNA) - Stock Titan
These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Sales Are Under Threat - Moomoo
The Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Sales Forecasts - Yahoo Finance
The $59B Quiet Shift Reshaping How Patients Access Care - Benzinga
How The Ginkgo Bioworks (DNA) Story Is Shifting After The Biosecurity Divestiture And Target Cut - Yahoo Finance
William Blair Maintains Ginkgo Bioworks(DNA.US) With Sell Rating - Moomoo
TradingKey - TradingKey
Number of shareholders of Ginkgo Bioworks Holdings Inc. – OTC:DNABW - TradingView
Ginkgo Bioworks Q1 Earnings Call Highlights - Barchart.com
Ginkgo Bioworks Earnings Call: Cash Rich, Revenue Pinched - TipRanks
DNA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2026 Earnings Call Transcript - Insider Monkey
Ginkgo Bioworks Holdings (DNA) TTM Net Loss Of US$312.8 Million Reinforces Bearish Narratives - Sahm
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Price, News, Quote & History - Yahoo Finance
Ginkgo Bioworks slumps 14% after projecting FY26 cash burn of $125M-$150M (DNA:NYSE) - Seeking Alpha
TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating Challenging Waters with a Pioneering Vision - DirectorsTalk Interviews
Ginkgo Bioworks Previously Reported Fincl Results for Comparable Periods Retrospectively Recast >DNA - Moomoo
Earnings call transcript: Ginkgo Bioworks Q1 2026 sees revenue drop, restructuring efforts noted - Investing.com Canada
Ginkgo Bioworks : Q1 2026 Results (Dial-In Information) - marketscreener.com
Ginkgo Bioworks : Q1 2026 Results Presentation - marketscreener.com
Ginkgo Bioworks : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Ginkgo Bioworks Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ginkgo Bioworks Holdings Inc. (DNA) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
Ginkgo Bioworks reports Q1 revenue decline, reaffirms cash burn By Investing.com - Investing.com South Africa
Ginkgo Bioworks reports Q1 revenue decline, reaffirms cash burn - Investing.com
Ginkgo Bioworks (NYSE: DNA) posts Q1 2026 loss and exits Biosecurity unit - Stock Titan
[8-K] Ginkgo Bioworks Holdings, Inc. Reports Material Event - Stock Titan
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab - Fidelity
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab – Company AnnouncementFT.com - Financial Times
(DNA) Volatility Zones as Tactical Triggers - Stock Traders Daily
An undisclosed buyer acquired Biosecurity business of Ginkgo Bioworks Holdings, Inc. - marketscreener.com
MSN Money - MSN
Benchling Launches One-Click Ordering for Biopharma R&D with Twist Bioscience, Adaptyv, and Ginkgo Bioworks - Yahoo Finance
Ginkgo Bioworks Holdings Inc expected to post a loss of $1.08 a shareEarnings Preview - TradingView
Ginkgo Bioworks Holdings Inc Stock (DNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):